Polomar Health Services Reports Revenue Surge to $1.01 Million, Net Loss Improves

Polomar Health Services, Inc. (formerly Trustfeed Corp.) reported significant financial improvements in its latest quarterly filing for the period ending March 31, 2026. The company generated revenue of $1.01 million, a substantial increase from just $4,542 in the same period last year. This growth is attributed to the transition of Polomar Pharmacy towards online fulfillment of compounded medications, particularly GLP-1 agonists, which has begun to yield revenue. The cost of goods sold also rose to $455,030, resulting in a gross profit of $550,489, compared to a mere $3,182 in the prior year.

Despite the increase in revenue, Polomar Health Services reported a net loss of $25,377 for the quarter, a notable improvement from the $456,855 loss recorded in the same quarter of 2025. Operating expenses increased to $557,391, primarily driven by higher sales and marketing costs, which rose to $311,457 from $19,754 a year earlier. The company’s total liabilities as of March 31, 2026, stood at $1.76 million, up from $1.61 million at the end of 2025, while stockholders’ deficit increased slightly to $1.25 million.

Strategically, Polomar has been expanding its operational capabilities and market reach. The company is actively seeking licenses to fulfill prescriptions in additional states, aiming to enhance its national presence. As of now, Polomar Pharmacy is licensed to operate in 28 states and plans to expand further in the third quarter of 2026. The company has also entered into a pharmacy services agreement with CareValidate, Inc., which has begun contributing to its revenue stream. Additionally, Polomar is preparing to launch SlimRx™, an online platform aimed at connecting patients with healthcare providers for weight loss medications, expected to go live in the third quarter of 2026.

Operationally, Polomar has faced challenges, including delays in product development and supply chain issues, which have impacted its ability to fully capitalize on its business model transition. The company has reported a decline in revenues from its previous focus on dermatological medications, but it is optimistic about the future as it continues to adapt its offerings. The company’s employee headcount remains stable, and it is focused on enhancing its fulfillment capacity to meet growing demand. Looking ahead, Polomar Health Services anticipates steady growth in its wholesale business as it adds new customers and expands its product offerings, despite the ongoing challenges in the market.